Annual report 2021 for Initiator Pharma A/S

Regulatory

Initiator Pharma’s annual report for 2021 is now available on the company´s home page

http://initiatorpharma.com/investors/financial-reports/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address [email protected] and phone number +46 8 121 576 90, is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma AnnualReport2021, FINAL

Documents